BioSpace News Archive

DarioHealth Corp., a leader in the global digital health market, announced a new agreement with a large regional health plan to deliver highly personalized digital health solutions to more than 160,000 Plan members living with hypertension.

Infinity Pharmaceuticals, Inc. announced that it has terminated its previously announced merger agreement providing for the merger with MEI Pharma, Inc. (“MEI”).

GRI Bio, Inc. today announced that it will present at the Virtual Investor – The GRI Opportunity Spotlight Event on Thursday, July 27, 2023 at 1:00 PM ET.

HDT Bio Corp. today announced the publication of preclinical data demonstrating that the company’s AMPLIFY vaccine platform holds a more favorable safety profile and increased durability and localization compared to repRNA vaccines delivered by lipid nanoparticles (LNPs), similar to those used to deliver currently-available RNA vaccines for COVID-19.

Aptitude Medical Systems has been awarded a significant grant from the Bill & Melinda Gates Foundation to develop point-of-care diagnostic tests for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis.

Oncocyte Corporation, a precision diagnostics company, announced that the Company will implement a 1-for-20 reverse stock split of the outstanding shares of its common stock.

Arcutis Biotherapeutics, Inc. announced that it will host a conference call and webcast at 4:30 p.m. ET on Tuesday, August 8, 2023, to report its second quarter financial results.

Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its second quarter 2023 financial results on Monday, August 7, 2023.

T2 Biosystems, Inc. (NASDAQ:TTOO), leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the second quarter 2023 after market close Monday, August 7, 2023.

Exagen Inc., a leading provider of autoimmune testing solutions, announced that Paul Kim has been appointed as a member of the Exagen Board of Directors, effective July 24, 2023.